A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
2d agoen
From the article
Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospital of Guangxi Medical University Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Dose-reduced thoracic radiotherapy shows promise for older and frail stage III NSCLC patients in randomized trial
This randomized open-label cohort trial by Wei-Xiang Qi and colleagues investigates whether dose-reduced thoracic radiotherapy can mitigate
plos.io·1mo ago
ClinicalKey
clinicalkey.com·1mo agoLung Cancer Patients on Drug From China’s Akeso Lived Longer
bloomberg.com·1mo ago
Traitements contre le cancer : «La Chine est en train de devenir le leader mondial du médicament»
l.liberation.fr·1mo ago
Mathematical modeling study identifies logistic model with ratio-dependent drug efficacy as best fit for NSCLC dynamics
This study evaluates which mathematical models best capture the eco-evolutionary dynamics of non-small cell lung cancer (NSCLC) by fitting t
journals.plos.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.